Once you agree to receive LUTATHERA
It’s important to tell your healthcare provider everything about your disease and health status. This should include:
- Symptoms you may have
- Any changes in your daily habits
- If you are trying to get pregnant, if you are already pregnant, or breastfeeding
- If you have trouble controlling when you urinate or have a bowel movement
- All the medicines you are taking
It is especially important to tell your healthcare provider if you are taking a type of medicine called a somatostatin analog. If you are taking one, you might have to stop or change your treatment for a short time before and while taking LUTATHERA.

Understanding radiation
Your doctor will give you tips to minimize radiation exposure to those around you throughout your treatment with LUTATHERA.

Reproductive safety

Before your first infusion

The day of therapy

The infusion
Approximately 1 hour before you are given LUTATHERA: You will be given a medicine that will help with any vomiting or an upset stomach that you may experience because of the treatment.
30 minutes before you are given LUTATHERA: You will be given amino acids through an intravenous (IV) infusion. This will help protect your kidneys. This infusion will take at least 4 hours. It will continue during and after you receive LUTATHERA.
The LUTATHERA infusion: Will take 30 to 40 minutes and is given as an IV infusion.

After the infusion
You will receive an injection of long-acting octreotide 30 mg after each LUTATHERA infusion.

Your next infusion
You and your healthcare provider will decide how many doses and how long between each dose is right for you.
Between each dose, your healthcare provider may check your liver, kidneys, and blood again.

After your last dose
What is LUTATHERA?
LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.
IMPORTANT SAFETY INFORMATION1
What is LUTATHERA?
LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.
IMPORTANT SAFETY INFORMATION1
What are some important things to know about the safety of LUTATHERA?
LUTATHERA is associated with some serious safety considerations, and in some cases these may require your healthcare provider to adjust or stop your treatment. You should always follow your healthcare provider’s instructions. Safety considerations include:
What are the most common side effects of LUTATHERA?
The most common and most serious side effects of LUTATHERA include: vomiting, nausea, decreased blood cell counts, increased liver enzymes, decreased blood potassium levels, and increased blood glucose.
Talk to your doctor if you experience any of these side effects. There are other possible side effects of LUTATHERA. For more information, and to learn more about LUTATHERA, talk to your doctor or healthcare provider.
What other medicines may interact with LUTATHERA?
Tell your healthcare provider if you are taking any other medications. Somatostatin analogs and corticosteroids may affect how your LUTATHERA treatment works. You should stop taking your long-acting somatostatin analog at least 4 weeks before LUTATHERA treatment. You may continue taking short-acting somatostatin analogs up to 24 hours before your LUTATHERA treatment. Avoid repeated high doses of glucocorticosteroids during treatment with LUTATHERA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information for LUTATHERA.
Distributed by: Advanced Accelerator Applications USA, Inc., NJ 07041
Reference: 1. LUTATHERA® [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; May 2020.